Statements (99)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Blueprint_Medicines
|
| gptkbp:activities |
RET inhibitor
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:FDA
gptkb:U._S._Food_and_Drug_Administration September 4, 2020 |
| gptkbp:brand |
gptkb:Gavreto
|
| gptkbp:class |
targeted therapy
antineoplastic agent kinase inhibitor |
| gptkbp:clinical_trial |
gptkb:ARROW_trial
high combination therapy Phase 1/2 monotherapy NC T03037385 NC T04194944 |
| gptkbp:composed_of |
synthetic organic compound
|
| gptkbp:contraindication |
severe hepatic impairment
hypersensitivity to pralsetinib |
| gptkbp:developed_by |
gptkb:Blueprint_Medicines
|
| gptkbp:developer |
gptkb:Blueprint_Medicines_Corporation
|
| gptkbp:discovered_by |
discovered in 2016
|
| gptkbp:dissolved |
soluble in DMSO
soluble in ethanol slightly soluble in water |
| gptkbp:dosage_form |
gptkb:tablet
400 mg once daily |
| gptkbp:effective_date |
September 2020
|
| gptkbp:excretion |
urine
feces |
| gptkbp:formulation |
tablet form
film-coated tablet |
| gptkbp:has_ability |
100 mg
400 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
Pralsetinib
|
| gptkbp:indication |
gptkb:healthcare_organization
gptkb:medullary_thyroid_cancer advanced solid tumors |
| gptkbp:ingredients |
gptkb:Pralsetinib
C22 H24 Cl N5 O2 S |
| gptkbp:interacts_with |
CY P3 A4 inducers
strong CY P3 A4 inducers strong CY P3 A4 inhibitors CY P3 A4 inhibitors |
| gptkbp:invention |
gptkb:US_Patent_10,000,000
patented |
| gptkbp:is_monitored_by |
blood pressure
liver function tests complete blood count |
| gptkbp:is_used_for |
treatment of cancer
treatment of RET fusion-positive non-small cell lung cancer |
| gptkbp:lifespan |
approximately 12 hours
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:metabolism |
liver
|
| gptkbp:pharmacokinetics |
oral bioavailability
metabolized by liver half-life of 13 hours inhibits RET signaling |
| gptkbp:population |
adults
pediatric patients |
| gptkbp:research_areas |
oncology
targeted therapy precision medicine |
| gptkbp:safety_features |
generally well tolerated
monitor blood counts risk of liver toxicity risk of gastrointestinal perforation monitor blood pressure risk of hypersensitivity reactions risk of bleeding monitor liver function risk of QT prolongation risk of renal impairment monitor electrolytes risk of embryo-fetal toxicity risk of interstitial lung disease |
| gptkbp:side_effect |
gptkb:fandom
fatigue nausea hypertension diarrhea rash liver enzyme elevation thrombocytopenia hypophosphatemia QT prolongation |
| gptkbp:social_structure |
gptkb:Cloud_Computing_Service
|
| gptkbp:storage |
store at room temperature
|
| gptkbp:targets |
RET gene
RET-altered thyroid cancer RET fusion-positive non-small cell lung cancer |
| gptkbp:type_of |
1394640-80-0
|
| gptkbp:weight |
429.97 g/mol
|